Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Wenfeng Xu

Wayne R Kindsvogel

Scott R Presnell

Zhi Chen

Yasmin A Chandrasekher

Steven D Hughes

Donald C Foster

Pallavur V Sivakumar

Brian A Fox

Stacey R Dillon

Anthony W Siadak

Margaret Dow Moore

Cameron Brandt

Joyce M Lehner

James D Kelly

Karen L Madden

Cindy A Sprecher

Julia E Novak

Mark W Rixon

Jane A Gross

Zeren Gao

Eugene C Yi

Stephen R Jaspers

Kevin M Klucher

Francis J Grant

Randal Henne

Jacob J Kennedy

Cameron S Brandt

Penny Thompson

Hal Blumberg

David P Yee

Yue Yao

Theodore E Whitmore

Catherine E Lofton-Day

Pallavar V Sivakumar

Maribeth A Eagan

Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

B7 family member zB7H6 and related compositions and methods

The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.

Anti-IL-20 antibodies and binding partners and methods of using in inflammation

The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.

Anti-IL-TIF antibodies

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.

Methods of producing anti-IL-22RA antibodies

A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

Methods of treating inflammatory disease using a soluble IL-20 receptor

Anti-IL-22RA antibodies and binding partners and methods of using in inflammation

The present invention provides methods of treating psoriasis in a subject (i.e., psoriasis associated with a joint disease), by administering to the subject an effective dose of a composition comprising a soluble IL-22R/IL-20RB heterodimeric polypeptide, wherein the heterodimeric polypeptide comprises an IL-22R extracellular domain covalently linked to an IL-20RB extracellular domain.

Soluble heterodimeric cytokine receptor

Methods of treatment using anti-IL-22RA antibodies

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as 'Zcytor16.'

Human cytokine receptor

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as 'Zcytor16' and uses thereof.

Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as 'Zcytor16.'

Anti-zB7H6 antibody-drug conjugates

Growing community of inventors

Mukilteo, WA, United States of America

Wenfeng Xu